{"protocolSection": {"identificationModule": {"nctId": "NCT01634113", "orgStudyIdInfo": {"id": "205.443"}, "secondaryIdInfos": [{"id": "2011-005512-28", "type": "EUDRACT_NUMBER", "domain": "EudraCT"}], "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat\u00ae Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma", "officialTitle": "A Phase II/III, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution (2.5 \u00b5g and 5 \u00b5g) Administered Once Daily in the Afternoon Via Respimat\u00ae Inhaler for 12 Weeks in Patients 1 to 5 Years Old With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2015-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-07"}, "primaryCompletionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-04-16", "studyFirstSubmitQcDate": "2012-07-03", "studyFirstPostDateStruct": {"date": "2012-07-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-06-03", "resultsFirstSubmitQcDate": "2015-06-03", "resultsFirstPostDateStruct": {"date": "2015-06-23", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-06-03", "lastUpdatePostDateStruct": {"date": "2015-06-23", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "The primary objective of this trial is to evaluate the safety and efficacy of two doses of tiotropium inhalation solution delivered via the Respimat\u00ae inhaler once daily in the afternoon in patients (1 to 5 years old) with persistent asthma on top of inhaled corticosteroid (ICS) treatment."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 102, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "tiotropium low dose", "type": "EXPERIMENTAL", "description": "Once daily, delivered with Respimat\u00ae inhaler", "interventionNames": ["Drug: tiotropium-bromide"]}, {"label": "tiotropium high dose", "type": "EXPERIMENTAL", "description": "Once daily, delivered with Respimat\u00ae inhaler", "interventionNames": ["Drug: tiotropium-bromide"]}, {"label": "placebo", "type": "PLACEBO_COMPARATOR", "description": "Once daily, delivered with Respimat\u00ae inhaler", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "tiotropium-bromide", "description": "IMP", "armGroupLabels": ["tiotropium high dose"]}, {"type": "DRUG", "name": "tiotropium-bromide", "description": "IMP", "armGroupLabels": ["tiotropium low dose"]}, {"type": "DRUG", "name": "placebo", "description": "placebo matching tiotropium", "armGroupLabels": ["placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Weekly Mean Combined Daytime Asthma Symptom Score", "description": "Change from baseline in the weekly mean combined daytime asthma symptom score as assessed by the Paediatric Asthma Caregivers Diary (PACD) in the last week of the 12 week treatment period.\n\nThe PACD is a diary designed to evaluate daily asthma symptoms in children aged 2-5 years. The diary consists of three questions to be answered each morning, when the child wakes up, and seven questions to be answered each evening, right after the child goes to bed for the night. A week was defined as 7 days.\n\nThe combined daytime score is the average of scores from questions 4 - 7 in the diary which are questions regarding severity of cough, wheezing, trouble breathing and interference with activities, scores for each question range from 0 (best) to 5 (worst). The week 12 weekly mean is the mean of the responses for each day averaged over the 7 days in week 12, so combined daytime asthma symptom scores also range from 0 (best) to 5 (worst).\n\nThe measured values presented are adjusted means.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "FEV1 Peak (0-3h) Change From Baseline", "description": "Change from baseline in peak Forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak (0-3h)) measured at week 12", "timeFrame": "10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12"}], "secondaryOutcomes": [{"measure": "Weekly Mean Overnight Asthma Symptom Score Response", "description": "Change from baseline in the weekly mean overnight asthma symptom score response as assessed by the PACD in the last week of the 12 week treatment period.\n\nThe overnight score is the score from the following question in the PACD, \"How much did your child cough last night after your child was put to bed for the night until he/she awoke this morning?\". This endpoint was determined only for patients with 2 or more nights with symptoms per week during the baseline period. In this case, the baseline period is the 7 days used to derive the baseline value. A patient has a night with symptoms if the question was answered with scores 1, 2, 3, 4 or 5 or the patient received \u03b2-Agonist at least one time since he/she went to bed. A week was defined as 7 days.\n\nScores range from 0 (best) to 4 (worst), a value of 5 indicates severity of symptoms is unknown.\n\nThe measured values presented are adjusted means", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Weekly Percentage of Days Without Asthma Symptoms", "description": "Weekly Percentage of days without asthma symptoms at week 12.\n\nA day without asthma symptoms was defined as a day during which the patient experienced no asthma symptoms, did not use rescue medication (salbutamol/albuterol) and had no asthma exacerbation/worsening requiring systemic corticosteroids, or unscheduled visits to a doctor's office, emergency department, or hospital. A week was defined as 7 days.\n\nThe measured values presented are adjusted means", "timeFrame": "12 weeks"}, {"measure": "Weekly Percentage of Days With Use of Salbutamol (Albuterol) Rescue Medication", "description": "Weekly percentage of days with use of salbutamol (albuterol) rescue medication at week 12. A week was defined as 7 days.", "timeFrame": "12 weeks"}, {"measure": "Weekly Mean Nighttime Awakenings Due to Asthma Symptoms", "description": "Change from baseline in the weekly mean nighttime awakenings due to asthma symptoms as assessed by the PACD, in the last week of the 12 week treatment period.\n\nThe weekly mean was calculated as the average of the weekly scores for the question \"Did your child wake up during the night due to his/her asthma?\" The question was answered on a 5-point verbal rating scale, with scores ranging from 1 (did not wake up) to 5 (was awake all night). A week was defined as 7 days.\n\nThe measured values presented are adjusted means", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Trough FEV1 Change From Baseline", "description": "Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "FEV1 AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 h for FEV1 (FEV1 AUC 0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).", "timeFrame": "10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12"}, {"measure": "FVC Peak (0-3h) Change From Baseline", "description": "Change from baseline in maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak (0-3h)) after 12 weeks of treatment.", "timeFrame": "10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12"}, {"measure": "Trough FVC Change From Baseline", "description": "Change from baseline of trough (pre-dose) forced vital capacity (FVC) measured 10 min before the administration of trial medication after 12 weeks of treatment.", "timeFrame": "Baseline and 12 weeks"}, {"measure": "FVC AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 h for FVC (FVC AUC0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).", "timeFrame": "10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12"}, {"measure": "Individual FEV1 Measurements", "description": "Change from baseline in individual FEV1 measurements at each timepoint after 12 weeks", "timeFrame": "Baseline and 12 weeks"}, {"measure": "Individual FVC Measurements", "description": "Change from baseline in individual FVC measurements at each timepoint after 12 weeks", "timeFrame": "Baseline and 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. All patients' parents (or legal guardians) must sign and date an informed consent consistent with ICH-GCP guidelines and local legislation prior to participation in the trial. Where appropriate, participants should assent to enroll in the study.\n2. Male or female patients between 1 and 5 years of age.\n3. By a physician documented (at least 6 month) history of persistent asthma symptoms, including (but not limited to) wheezing, cough, and/or shortness of breath. (persistent = need for inhalation corticosteroid maintenance therapy to control asthma symptoms)\n4. For patients aged 5 years and capable of performing technically acceptable Pulmonary Function tests (PFTs): documented impaired lung function (i.e. pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) is smaller or equal to 90% of predicted normal).\n5. All patients must have been on maintenance treatment with an inhaled corticosteroid at stable dose, either as mono treatment or in combination with another controller medication, for at least 4 weeks before Visit 1.\n6. All patients must be symptomatic (partly controlled) as defined by the Global Initiative for Asthma (GINA) guideline for children aged 5 years and younger in the week prior to Visit 1 (screening) and in the week prior to randomisation (Visit 2).\n\nFurther inclusion criteria apply.\n\nExclusion criteria:\n\n1. Patients with a significant disease other than asthma.\n2. Patients with clinically relevant abnormal screening haematology or blood chemistry will be excluded if the abnormality defines a significant disease as defined in exclusion criterion 1.\n3. Patients with a history of congenital or acquired heart disease, or patients who have been hospitalised for cardiac syncope or failure during the past year.\n4. Patients with any unstable or life-threatening cardiac arrhythmia, including cardiac arrhythmia requiring intervention (e.g. pacemaker implantation) or a change in drug therapy within the past year.\n5. Patients with a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy.\n6. Patients with clinically significant lung diseases other than asthma.\n7. Alternative causes (other causes than asthma) that can lead to respiratory symptoms of wheeze, cough and shortness of breath.\n8. Patients with known active tuberculosis.\n9. Patients who have undergone thoracotomy with pulmonary resection.\n10. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit 1).\n\nFurther exclusion criteria apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "1 Year", "maximumAge": "5 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "205.443.12003 Boehringer Ingelheim Investigational Site", "city": "Columbia", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 38.95171, "lon": -92.33407}}, {"facility": "205.443.12005 Boehringer Ingelheim Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "205.443.12006 Boehringer Ingelheim Investigational Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "205.443.12004 Boehringer Ingelheim Investigational Site", "city": "Summerville", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 33.0185, "lon": -80.17565}}, {"facility": "205.443.01004 Boehringer Ingelheim Investigational Site", "city": "Antwerpen", "country": "Belgium", "geoPoint": {"lat": 51.21989, "lon": 4.40346}}, {"facility": "205.443.01002 Boehringer Ingelheim Investigational Site", "city": "Brussel", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "205.443.01001 Boehringer Ingelheim Investigational Site", "city": "Edegem", "country": "Belgium", "geoPoint": {"lat": 51.15662, "lon": 4.44504}}, {"facility": "205.443.02002 Boehringer Ingelheim Investigational Site", "city": "Helsinki", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "205.443.02003 Boehringer Ingelheim Investigational Site", "city": "Turku", "country": "Finland", "geoPoint": {"lat": 60.45148, "lon": 22.26869}}, {"facility": "205.443.03003 Boehringer Ingelheim Investigational Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "205.443.03001 Boehringer Ingelheim Investigational Site", "city": "Bochum", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "205.443.03002 Boehringer Ingelheim Investigational Site", "city": "Ettenheim", "country": "Germany", "geoPoint": {"lat": 48.25696, "lon": 7.81247}}, {"facility": "205.443.03010 Boehringer Ingelheim Investigational Site", "city": "Frankfurt", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "205.443.82003 Boehringer Ingelheim Investigational Site", "city": "Guri", "country": "Korea, Republic of", "geoPoint": {"lat": 37.5986, "lon": 127.1394}}, {"facility": "205.443.82002 Boehringer Ingelheim Investigational Site", "city": "Incheon", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "205.443.82001 Boehringer Ingelheim Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "205.443.05001 Boehringer Ingelheim Investigational Site", "city": "Balvi", "country": "Latvia", "geoPoint": {"lat": 57.1313, "lon": 27.26583}}, {"facility": "205.443.05003 Boehringer Ingelheim Investigational Site", "city": "Rezekne", "country": "Latvia", "geoPoint": {"lat": 56.51025, "lon": 27.33994}}, {"facility": "205.443.05002 Boehringer Ingelheim Investigational Site", "city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "205.443.06002 Boehringer Ingelheim Investigational Site", "city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "205.443.06003 Boehringer Ingelheim Investigational Site", "city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "205.443.10002 Boehringer Ingelheim Investigational Site", "city": "Kelantan", "country": "Malaysia"}, {"facility": "205.443.10001 Boehringer Ingelheim Investigational Site", "city": "Kuala Lumpur", "country": "Malaysia", "geoPoint": {"lat": 3.1412, "lon": 101.68653}}, {"facility": "205.443.10003 Boehringer Ingelheim Investigational Site", "city": "Pahang", "country": "Malaysia"}, {"facility": "205.443.04003 Boehringer Ingelheim Investigational Site", "city": "Breda", "country": "Netherlands", "geoPoint": {"lat": 51.58656, "lon": 4.77596}}, {"facility": "205.443.04001 Boehringer Ingelheim Investigational Site", "city": "Groningen", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "205.443.09001 Boehringer Ingelheim Investigational Site", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "205.443.09002 Boehringer Ingelheim Investigational Site", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "205.443.07003 Boehringer Ingelheim Investigational Site", "city": "Dnipropetrovsk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "205.443.07002 Boehringer Ingelheim Investigational Site", "city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "205.443.07005 Boehringer Ingelheim Investigational Site", "city": "Vinnytsya", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "205.443.07004 Boehringer Ingelheim Investigational Site", "city": "Zaporizhya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "205.443.07001 Boehringer Ingelheim Investigational Site", "city": "Zaporizhzhya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}]}, "referencesModule": {"references": [{"pmid": "29605203", "type": "DERIVED", "citation": "Wachtel H, Nagel M, Engel M, El Azzi G, Sharma A, Suggett J. In vitro and clinical characterization of the valved holding chamber AeroChamber Plus(R) Flow-Vu(R) for administrating tiotropium Respimat(R) in 1-5-year-old children with persistent asthmatic symptoms. Respir Med. 2018 Apr;137:181-190. doi: 10.1016/j.rmed.2018.03.010. Epub 2018 Mar 7."}, {"pmid": "29361462", "type": "DERIVED", "citation": "Vrijlandt EJLE, El Azzi G, Vandewalker M, Rupp N, Harper T, Graham L, Szefler SJ, Moroni-Zentgraf P, Sharma A, Vulcu SD, Sigmund R, Chawes B, Engel M, Bisgaard H. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2018 Feb;6(2):127-137. doi: 10.1016/S2213-2600(18)30012-2. Epub 2018 Jan 18."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "FG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "FG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "36"}, {"groupId": "FG002", "numSubjects": "32"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "36"}, {"groupId": "FG002", "numSubjects": "31"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Not treated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Treated set which included all randomised patients who received at least one dose of trial medication", "groups": [{"id": "BG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "BG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "BG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "31"}, {"groupId": "BG003", "value": "101"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.2", "spread": "1.4"}, {"groupId": "BG001", "value": "3.1", "spread": "1.5"}, {"groupId": "BG002", "value": "3.1", "spread": "1.3"}, {"groupId": "BG003", "value": "3.1", "spread": "1.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "40"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "61"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Weekly Mean Combined Daytime Asthma Symptom Score", "description": "Change from baseline in the weekly mean combined daytime asthma symptom score as assessed by the Paediatric Asthma Caregivers Diary (PACD) in the last week of the 12 week treatment period.\n\nThe PACD is a diary designed to evaluate daily asthma symptoms in children aged 2-5 years. The diary consists of three questions to be answered each morning, when the child wakes up, and seven questions to be answered each evening, right after the child goes to bed for the night. A week was defined as 7 days.\n\nThe combined daytime score is the average of scores from questions 4 - 7 in the diary which are questions regarding severity of cough, wheezing, trouble breathing and interference with activities, scores for each question range from 0 (best) to 5 (worst). The week 12 weekly mean is the mean of the responses for each day averaged over the 7 days in week 12, so combined daytime asthma symptom scores also range from 0 (best) to 5 (worst).\n\nThe measured values presented are adjusted means.", "populationDescription": "Full analysis set, which included all randomised patients who received at least one dose of trial medication, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.456", "spread": "0.084"}, {"groupId": "OG001", "value": "-0.535", "spread": "0.082"}, {"groupId": "OG002", "value": "-0.504", "spread": "0.089"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4963", "pValueComment": "All treatment comparisons were exploratory, no formal hypothesis testing was performed.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.080", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.312", "ciUpperLimit": "0.152", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.117", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6936", "pValueComment": "All treatment comparisons were exploratory, no formal hypothesis testing was performed.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.048", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.292", "ciUpperLimit": "0.195", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.123", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "PRIMARY", "title": "FEV1 Peak (0-3h) Change From Baseline", "description": "Change from baseline in peak Forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak (0-3h)) measured at week 12", "populationDescription": "Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litres", "timeFrame": "10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.158", "spread": "0.026"}, {"groupId": "OG001", "value": "0.130", "spread": "0.125"}, {"groupId": "OG002", "value": "0.145", "spread": "0.078"}]}]}]}, {"type": "SECONDARY", "title": "Weekly Mean Overnight Asthma Symptom Score Response", "description": "Change from baseline in the weekly mean overnight asthma symptom score response as assessed by the PACD in the last week of the 12 week treatment period.\n\nThe overnight score is the score from the following question in the PACD, \"How much did your child cough last night after your child was put to bed for the night until he/she awoke this morning?\". This endpoint was determined only for patients with 2 or more nights with symptoms per week during the baseline period. In this case, the baseline period is the 7 days used to derive the baseline value. A patient has a night with symptoms if the question was answered with scores 1, 2, 3, 4 or 5 or the patient received \u03b2-Agonist at least one time since he/she went to bed. A week was defined as 7 days.\n\nScores range from 0 (best) to 4 (worst), a value of 5 indicates severity of symptoms is unknown.\n\nThe measured values presented are adjusted means", "populationDescription": "Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.671", "spread": "0.110"}, {"groupId": "OG001", "value": "-0.588", "spread": "0.111"}, {"groupId": "OG002", "value": "-0.655", "spread": "0.116"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5995", "pValueComment": "All treatment comparisons were exploratory, no formal hypothesis testing was performed.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.083", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.229", "ciUpperLimit": "0.394", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.157", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9251", "pValueComment": "All treatment comparisons were exploratory, no formal hypothesis testing was performed.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.015", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.303", "ciUpperLimit": "0.333", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.160", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Weekly Percentage of Days Without Asthma Symptoms", "description": "Weekly Percentage of days without asthma symptoms at week 12.\n\nA day without asthma symptoms was defined as a day during which the patient experienced no asthma symptoms, did not use rescue medication (salbutamol/albuterol) and had no asthma exacerbation/worsening requiring systemic corticosteroids, or unscheduled visits to a doctor's office, emergency department, or hospital. A week was defined as 7 days.\n\nThe measured values presented are adjusted means", "populationDescription": "Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of days", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53.151", "spread": "7.405"}, {"groupId": "OG001", "value": "55.401", "spread": "7.181"}, {"groupId": "OG002", "value": "50.654", "spread": "7.873"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8279", "pValueComment": "All treatment comparisons were exploratory, no formal hypothesis testing was performed.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "2.250", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.243", "ciUpperLimit": "22.743", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "10.324", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8181", "pValueComment": "All treatment comparisons were exploratory, no formal hypothesis testing was performed.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-2.497", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.987", "ciUpperLimit": "18.994", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "10.826", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Weekly Percentage of Days With Use of Salbutamol (Albuterol) Rescue Medication", "description": "Weekly percentage of days with use of salbutamol (albuterol) rescue medication at week 12. A week was defined as 7 days.", "populationDescription": "Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of days", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24.94", "spread": "36.80"}, {"groupId": "OG001", "value": "24.23", "spread": "36.86"}, {"groupId": "OG002", "value": "24.88", "spread": "38.45"}]}]}]}, {"type": "SECONDARY", "title": "Weekly Mean Nighttime Awakenings Due to Asthma Symptoms", "description": "Change from baseline in the weekly mean nighttime awakenings due to asthma symptoms as assessed by the PACD, in the last week of the 12 week treatment period.\n\nThe weekly mean was calculated as the average of the weekly scores for the question \"Did your child wake up during the night due to his/her asthma?\" The question was answered on a 5-point verbal rating scale, with scores ranging from 1 (did not wake up) to 5 (was awake all night). A week was defined as 7 days.\n\nThe measured values presented are adjusted means", "populationDescription": "Full analysis set, including patients with available endpoint data at week 12. Missing data in a week was imputed by the available data from the patient during that week, for weeks where data was completely missing no imputation was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "31"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.318", "spread": "0.080"}, {"groupId": "OG001", "value": "-0.257", "spread": "0.078"}, {"groupId": "OG002", "value": "-0.392", "spread": "0.084"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5869", "pValueComment": "All treatment comparisons were exploratory, no formal hypothesis testing was performed.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "0.061", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.161", "ciUpperLimit": "0.283", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.112", "estimateComment": "Difference calculated as Tio R2.5 minus placebo"}, {"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5230", "pValueComment": "All treatment comparisons were exploratory, no formal hypothesis testing was performed.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.075", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.305", "ciUpperLimit": "0.156", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.116", "estimateComment": "Difference calculated as Tio R5 minus placebo"}]}, {"type": "SECONDARY", "title": "Trough FEV1 Change From Baseline", "description": "Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 12.", "populationDescription": "Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.060", "spread": "0.032"}, {"groupId": "OG001", "value": "0.017", "spread": "0.108"}, {"groupId": "OG002", "value": "0.085", "spread": "0.163"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 h for FEV1 (FEV1 AUC 0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).", "populationDescription": "Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litres", "timeFrame": "10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.104", "spread": "0.043"}, {"groupId": "OG001", "value": "0.072", "spread": "0.114"}, {"groupId": "OG002", "value": "0.077", "spread": "0.116"}]}]}]}, {"type": "SECONDARY", "title": "FVC Peak (0-3h) Change From Baseline", "description": "Change from baseline in maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak (0-3h)) after 12 weeks of treatment.", "populationDescription": "Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litres", "timeFrame": "10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.210", "spread": "0.054"}, {"groupId": "OG001", "value": "0.136", "spread": "0.143"}, {"groupId": "OG002", "value": "0.060", "spread": "0.085"}]}]}]}, {"type": "SECONDARY", "title": "Trough FVC Change From Baseline", "description": "Change from baseline of trough (pre-dose) forced vital capacity (FVC) measured 10 min before the administration of trial medication after 12 weeks of treatment.", "populationDescription": "Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.155", "spread": "0.060"}, {"groupId": "OG001", "value": "-0.027", "spread": "0.133"}, {"groupId": "OG002", "value": "-0.050", "spread": "0.226"}]}]}]}, {"type": "SECONDARY", "title": "FVC AUC (0-3h) Change From Baseline", "description": "Change from baseline of area under the curve (AUC) from 0 to 3 h for FVC (FVC AUC0-3h) after 12 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).", "populationDescription": "Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litres", "timeFrame": "10 minutes before drug administration and 30 minutes, 1 hour (h), 2h and 3h after drug administration at baseline and week 12", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.164", "spread": "0.037"}, {"groupId": "OG001", "value": "0.035", "spread": "0.105"}, {"groupId": "OG002", "value": "0.003", "spread": "0.130"}]}]}]}, {"type": "SECONDARY", "title": "Individual FEV1 Measurements", "description": "Change from baseline in individual FEV1 measurements at each timepoint after 12 weeks", "populationDescription": "Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"title": "Time: 0 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.03"}, {"groupId": "OG001", "value": "0.02", "spread": "0.11"}, {"groupId": "OG002", "value": "0.09", "spread": "0.16"}]}]}, {"title": "Time: 30 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "spread": "0.09"}, {"groupId": "OG001", "value": "0.03", "spread": "0.13"}, {"groupId": "OG002", "value": "0.12", "spread": "0.11"}]}]}, {"title": "Time: 1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "spread": "0.08"}, {"groupId": "OG001", "value": "0.10", "spread": "0.13"}, {"groupId": "OG002", "value": "0.12", "spread": "0.04"}]}]}, {"title": "Time: 2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.05"}, {"groupId": "OG001", "value": "0.09", "spread": "0.13"}, {"groupId": "OG002", "value": "0.04", "spread": "0.16"}]}]}, {"title": "Time: 3 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "spread": "0.05"}, {"groupId": "OG001", "value": "0.06", "spread": "0.13"}, {"groupId": "OG002", "value": "0.05", "spread": "0.11"}]}]}]}, {"type": "SECONDARY", "title": "Individual FVC Measurements", "description": "Change from baseline in individual FVC measurements at each timepoint after 12 weeks", "populationDescription": "Full analysis set including only 5 years olds capable of providing technically acceptable pulmonary function tests (PFTs). No imputation for missing data was employed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Litres", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler"}, {"id": "OG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"title": "Time: 0 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.06"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.13"}, {"groupId": "OG002", "value": "-0.05", "spread": "0.23"}]}]}, {"title": "Time: 30 minutes", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.07"}, {"groupId": "OG001", "value": "0.04", "spread": "0.15"}, {"groupId": "OG002", "value": "0.06", "spread": "0.08"}]}]}, {"title": "Time: 1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.18", "spread": "0.04"}, {"groupId": "OG001", "value": "0.06", "spread": "0.14"}, {"groupId": "OG002", "value": "0.05", "spread": "0.10"}]}]}, {"title": "Time: 2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.04"}, {"groupId": "OG001", "value": "0.02", "spread": "0.10"}, {"groupId": "OG002", "value": "-0.03", "spread": "0.16"}]}]}, {"title": "Time: 3 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.19", "spread": "0.07"}, {"groupId": "OG001", "value": "0.04", "spread": "0.13"}, {"groupId": "OG002", "value": "-0.03", "spread": "0.13"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first drug intake until 30 days after last drug intake, up to 119 days", "eventGroups": [{"id": "EG000", "title": "Placebo Respimat", "description": "Inhalation of placebo solution once daily for 12 weeks, delivered by the Respimat Inhaler", "seriousNumAffected": 3, "seriousNumAtRisk": 34, "otherNumAffected": 24, "otherNumAtRisk": 34}, {"id": "EG001", "title": "Tio R2.5", "description": "Inhalation of 2.5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler", "seriousNumAffected": 0, "seriousNumAtRisk": 36, "otherNumAffected": 19, "otherNumAtRisk": 36}, {"id": "EG002", "title": "Tio R5", "description": "Inhalation of 5\u03bcg tiotropium bromide solution once daily for 12 weeks, delivered by the Respimat Inhaler.", "seriousNumAffected": 0, "seriousNumAtRisk": 31, "otherNumAffected": 16, "otherNumAtRisk": 31}], "seriousEvents": [{"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Bronchopneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}], "otherEvents": [{"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 31}]}, {"term": "Mouth ulceration", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 31}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 31}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 31}]}, {"term": "Ear infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 31}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 31}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 31}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 31}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 31}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 31}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 31}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 31}]}, {"term": "Balanoposthitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 31}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 31}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 31}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 31}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 31}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MEDDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 34}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 31}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Peru"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001965", "term": "Bromides"}, {"id": "D000069447", "term": "Tiotropium Bromide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000010276", "term": "Parasympatholytics"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000927", "term": "Anticonvulsants"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M5241", "name": "Bromides", "asFound": "Root", "relevance": "HIGH"}, {"id": "M416", "name": "Tiotropium Bromide", "asFound": "Metabolites", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M13189", "name": "Parasympatholytics", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}